A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

Richard Rupp, D. Hurley, S. Grayson, J. Li, K. Nolan, R. D. McFetridge, J. Hartzel, C. Abeygunawardana, M. Winters, H. Pujar, P. Benner, L. Musey

Research output: Contribution to journalArticle

Abstract

Background: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant. Methods: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12–15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants. Results: Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant. Conclusion: PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.

Original languageEnglish (US)
Pages (from-to)549-559
Number of pages11
JournalHuman Vaccines and Immunotherapeutics
Volume15
Issue number3
DOIs
StatePublished - Mar 4 2019

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Polysaccharides
Immunoglobulin G
Antibody Formation
Vaccines
Serogroup
Young Adult
Vaccination
Safety

Keywords

  • immunogenicity
  • Pneumococcal conjugate vaccine
  • safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. / Rupp, Richard; Hurley, D.; Grayson, S.; Li, J.; Nolan, K.; McFetridge, R. D.; Hartzel, J.; Abeygunawardana, C.; Winters, M.; Pujar, H.; Benner, P.; Musey, L.

In: Human Vaccines and Immunotherapeutics, Vol. 15, No. 3, 04.03.2019, p. 549-559.

Research output: Contribution to journalArticle

Rupp, R, Hurley, D, Grayson, S, Li, J, Nolan, K, McFetridge, RD, Hartzel, J, Abeygunawardana, C, Winters, M, Pujar, H, Benner, P & Musey, L 2019, 'A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants' Human Vaccines and Immunotherapeutics, vol. 15, no. 3, pp. 549-559. https://doi.org/10.1080/21645515.2019.1568159
Rupp, Richard ; Hurley, D. ; Grayson, S. ; Li, J. ; Nolan, K. ; McFetridge, R. D. ; Hartzel, J. ; Abeygunawardana, C. ; Winters, M. ; Pujar, H. ; Benner, P. ; Musey, L. / A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. In: Human Vaccines and Immunotherapeutics. 2019 ; Vol. 15, No. 3. pp. 549-559.
@article{38a0ed389520435db3b3cba96469971c,
title = "A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants",
abstract = "Background: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant. Methods: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12–15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants. Results: Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant. Conclusion: PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.",
keywords = "immunogenicity, Pneumococcal conjugate vaccine, safety",
author = "Richard Rupp and D. Hurley and S. Grayson and J. Li and K. Nolan and McFetridge, {R. D.} and J. Hartzel and C. Abeygunawardana and M. Winters and H. Pujar and P. Benner and L. Musey",
year = "2019",
month = "3",
day = "4",
doi = "10.1080/21645515.2019.1568159",
language = "English (US)",
volume = "15",
pages = "549--559",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

AU - Rupp, Richard

AU - Hurley, D.

AU - Grayson, S.

AU - Li, J.

AU - Nolan, K.

AU - McFetridge, R. D.

AU - Hartzel, J.

AU - Abeygunawardana, C.

AU - Winters, M.

AU - Pujar, H.

AU - Benner, P.

AU - Musey, L.

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Background: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant. Methods: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12–15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants. Results: Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant. Conclusion: PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.

AB - Background: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant. Methods: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants. Adults received single dose and infants received 4 doses at 2, 4, 6, and 12–15 months of age. Adverse events (AEs) were collected after each dose. Serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) were measured prior and 30 days postvaccination in adults, at 1 month postdose 3 (PD3), pre-dose4, and postdose 4 (PD4) in infants. Results: Safety profiles were comparable across vaccination groups. At PD3, serotype-specific IgG GMCs were generally lower for either PCV15 formulation than PCV13 for most shared serotypes. PCV15 consistently elicited higher antibody responses to the 2 serotypes unique to the vaccine (22F and 33F) and serotype 3 for which PCV13 was shown to be ineffective. Except for serotypes 6A and 6B, no dose-response effect was observed with increasing concentrations of PnPs and/or adjuvant. Conclusion: PCV15 is safe and induces IgG and OPA responses to all 15 serotypes in the vaccine. No significant differences in antibody responses were observed with increases in PnPs and/or Aluminum Phosphate Adjuvant.

KW - immunogenicity

KW - Pneumococcal conjugate vaccine

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85063605057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063605057&partnerID=8YFLogxK

U2 - 10.1080/21645515.2019.1568159

DO - 10.1080/21645515.2019.1568159

M3 - Article

VL - 15

SP - 549

EP - 559

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 3

ER -